Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

8.73
-0.2200-2.46%
Post-market: 8.730.00000.00%16:36 EDT
Volume:1.10M
Turnover:9.65M
Market Cap:1.39B
PE:-7.59
High:8.93
Open:8.79
Low:8.58
Close:8.95
Loading ...

Ocular Therapeutix: Q4 Earnings Snapshot

Associated Press Finance
·
03 Mar

Earnings Flash (OCUL) Ocular Therapeutix Posts Q4 Net Loss $-0.29 a Share, vs. FactSet Est of $-0.25 Loss

MT Newswires Live
·
03 Mar

Ocular Therapeutix Q4 2024 GAAP EPS $(0.29) Misses $(0.24) Estimate, Sales $17.08M Miss $17.20M Estimate

Benzinga
·
03 Mar

BRIEF-Ocular Therapeutix Q4 EPS USD -0.29

Reuters
·
03 Mar

Ocular Therapeutix Q4 Product Revenue USD 17.02 Million

THOMSON REUTERS
·
03 Mar

Ocular Therapeutix Inc: Currently Does Not Intend to Raise Additional Capital This Year

THOMSON REUTERS
·
03 Mar

Ocular Therapeutix™ Reports Fourth Quarter and Full Year 2024 Results and Business Highlights

GlobeNewswire
·
03 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Amneal (AMRX) Soars 6.0%: Is Further Upside Left in the Stock?

Zacks
·
25 Feb

Ocular Therapeutix™ to Report Fourth Quarter and Full Year 2024 Results on March 3, 2025

GlobeNewswire
·
24 Feb

Piper Sandler Sticks to Their Buy Rating for Ocular Therapeutix (OCUL)

TIPRANKS
·
10 Feb

Ocular Therapeutix reports inducement grant under Nasdaq listing rule

TIPRANKS
·
17 Jan

Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
17 Jan

Piper Sandler Keeps Their Buy Rating on Ocular Therapeutix (OCUL)

TIPRANKS
·
16 Jan

Ocular Therapeutix (OCUL) Gets a Buy from TD Cowen

TIPRANKS
·
15 Jan

Ocular Therapeutix Inc: Plans to Seek FDA Feedback in H1 2025 on Clinical Trial Design for Axpaxli in Npdr

THOMSON REUTERS
·
14 Jan

Ocular Therapeutix Inc: First Wet Amd Registrational Trial, Sol-1, Completed Randomization in December 2024 With Topline Data Anticipated in Q4 2025

THOMSON REUTERS
·
14 Jan

Ocular Therapeutix™ Shares Sol-R Enrollment Progress and Next Steps for Axpaxli™ in Npdr

THOMSON REUTERS
·
14 Jan

Investors push Ocular Therapeutix (NASDAQ:OCUL) 6.3% lower this week, company's increasing losses might be to blame

Simply Wall St.
·
11 Jan

Ocular Therapeutix™ to Provide Corporate Update During 43Rd Annual J.p. Morgan Healthcare Conference Presentation

THOMSON REUTERS
·
08 Jan